Stimulant medications, like methylphenidate and amphetamines, have adverse cardiovascular effects, like elevated blood pressure, increasing the risk of cardiovascular events. Join host Geoff Wall as he reviews a new meta-analysis trying to quantify the risk of ADHD medications on cardiovascular outcomes.

The GameChanger
A large meta-analysis did not find an association between medications for ADHD and cardiovascular disease. Several limitations may interfere with the applicability of these results.

Show Segments
00:00 - Introductions
01:38 - Background on ADHD and Stimulant Medications
02:58 - Rationale for Analysis
06:42 - Looking at the Meta-Analysis
11:44 - The GameChanger: Meta-Analysis Findings
17:43 - Connecting to Practice: Addressing Patient Concerns
20:00 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the purported mechanism of the potential risk of cardiovascular disease in patients taking stimulant medications
2. Discuss the findings of a recent meta-analysis by Zhang et al on cardiovascular disease and stimulant medications

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-016-H01-P
Initial release date: 01/03/2023
Expiration date: 01/03/2024
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram